AstraZeneca to acquire Fusion for $2 billion

AstraZeneca plc announced on Tuesday that it will acquire Fusion Pharmaceuticals Inc. for $21 per share or a total of approximately $2 billion, “a 97% premium to Fusion’s closing market pri…